1-2 of 2
Magdalena Rodak
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer

Magdalena Rodak, Yana Dekempeneer, Maria Wojewódzka, Vicky Caveliers, Peter Covens, Brian W. Miller, Matthijs B. Sevenois, Frank Bruchertseifer, Alfred Morgenstern, Tony Lahoutte, Matthias D'Huyvetter, Marek Pruszyński
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (12): 1835–1845.
https://doi.org/10.1158/1535-7163.MCT-21-1021
Published: 02 December 2022
View article titled, Preclinical Evaluation of <sup>225</sup>Ac-Labeled Single-Domain Antibody for the Treatment of HER2<sup>pos</sup> Cancer
Open the PDF for Preclinical Evaluation of <sup>225</sup>Ac-Labeled Single-Domain Antibody for the Treatment of HER2<sup>pos</sup> Cancer in another window
Includes: Supplementary data
Journal Articles

The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy

Janik Puttemans, Benoit Stijlemans, Marleen Keyaerts, Sam Vander Meeren, Wim Renmans, Karel Fostier, Pieterjan Debie, Heleen Hanssens, Magdalena Rodak, Marek Pruszynski, Kim De Veirman, Karin Vanderkerken, Tony Lahoutte, Alfred Morgenstern, Frank Bruchertseifer, Nick Devoogdt, Matthias D'Huyvetter
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (1): 159–169.
https://doi.org/10.1158/1535-7163.MCT-21-0220
Published: 01 January 2022
View article titled, The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy
Open the PDF for The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy in another window
Includes: Supplementary data